Physician profile
Ashley E Wheeler
NPI 1497401905
$7,399.48
in general payments reported to CMS, 2019-2025
47 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,203 · 2023: $1,269 · 2024: $1,743 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,767 · Consulting Fee: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,766.72 |
| Consulting Fee | $430.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,072.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $770.95 | 2022-2025 | |
| Chiesi USA, INC. | $634.19 | 2022-2025 | Ferriprox |
| Astrazeneca Pharmaceuticals LP | $478.34 | 2022-2025 | Imfinzi, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $388.77 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $305.01 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Eisai INC. | $286.02 | 2022-2024 | |
| Incyte Corporation | $282.40 | 2022-2025 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $275.95 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Global Blood Therapeutics, INC. | $223.79 | 2022 | |
| Emmaus Medical, INC. | $190.44 | 2024-2025 | Endari |
| Pfizer INC. | $178.84 | 2022-2025 | |
| Genentech USA, INC. | $156.50 | 2023-2025 | Polivy, Itovebi, Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $143.23 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Alexion Pharmaceuticals, INC. | $140.65 | 2022-2024 | Ultomiris |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $139.69 | 2022-2025 | |
| Stemline Therapeutics INC. | $122.72 | 2023-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $112.18 | 2022-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $109.62 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Amgen INC. | $101.83 | 2022-2023 | Kyprolis |
| Emd Serono, INC. | $95.64 | 2023-2025 | Bavencio |
| Aveo Pharmaceuticals, INC. | $94.86 | 2022-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $87.46 | 2022-2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $81.83 | 2022-2024 | |
| Abbvie INC. | $73.70 | 2024-2025 | |
| Astellas Pharma US INC | $71.94 | 2024 | Padcev, Vyloy |
| Glaxosmithkline, LLC. | $65.31 | 2022-2025 | Ojjaara |
| Adaptive Biotechnologies Corporation | $63.22 | 2024-2025 | Clonoseq |
| Beigene USA, INC. | $62.15 | 2023-2024 | Brukinsa |
| Genzyme Corporation | $61.66 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $54.19 | 2023-2024 | Empaveli |
| Gilead Sciences, INC. | $53.69 | 2024-2025 | Trodelvy |
| Morphosys, US INC. | $51.46 | 2022-2023 | Monjuvi |
| Blueprint Medicines Corporation | $40.67 | 2022 | |
| Genmab U.S., INC. | $40.61 | 2024-2025 | Tivdak |
| Beone Medicines USA, INC. | $40.36 | 2025 | Brukinsa |
| Exelixis INC. | $36.89 | 2024-2025 | Cabometyx |
| G1 Therapeutics, INC. | $29.65 | 2022-2023 | Cosela |
| Taiho Oncology, INC. | $23.63 | 2024 | |
| Sobi, INC | $23.51 | 2022 | |
| Progenics Pharmaceuticals, INC. | $22.40 | 2023 | Pylarify |
| Lilly USA, LLC | $21.84 | 2022 | |
| Servier Pharmaceuticals LLC | $20.73 | 2025 | |
| Syndax Pharmaceuticals, INC. | $19.82 | 2025 | |
| Cti Biopharma Corp. | $19.42 | 2023 | Vonjo |
| Seagen INC. | $15.96 | 2023 | Tukysa |
| Janssen Pharmaceuticals, INC | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.